284 related articles for article (PubMed ID: 23438184)
1. SGLT2 inhibition: a novel prospective strategy in treatment of diabetes mellitus.
Deshmukh AB; Patel MC; Mishra B
Ren Fail; 2013; 35(4):566-72. PubMed ID: 23438184
[TBL] [Abstract][Full Text] [Related]
2. SGLT2 inhibitors: a promising new therapeutic option for treatment of type 2 diabetes mellitus.
Misra M
J Pharm Pharmacol; 2013 Mar; 65(3):317-27. PubMed ID: 23356840
[TBL] [Abstract][Full Text] [Related]
3. Sodium-glucose cotransporter inhibition: therapeutic potential for the treatment of type 2 diabetes mellitus.
Raskin P
Diabetes Metab Res Rev; 2013 Jul; 29(5):347-56. PubMed ID: 23463735
[TBL] [Abstract][Full Text] [Related]
4. Impact of sodium glucose cotransporter 2 inhibitors on weight in patients with type 2 diabetes mellitus.
Barnett AH
Postgrad Med; 2013 Sep; 125(5):92-100. PubMed ID: 24113667
[TBL] [Abstract][Full Text] [Related]
5. SGLT2 inhibitors to control glycemia in type 2 diabetes mellitus: a new approach to an old problem.
Jabbour SA
Postgrad Med; 2014 Jan; 126(1):111-7. PubMed ID: 24393758
[TBL] [Abstract][Full Text] [Related]
6. The role of the kidneys in glucose homeostasis: a new path towards normalizing glycaemia.
DeFronzo RA; Davidson JA; Del Prato S
Diabetes Obes Metab; 2012 Jan; 14(1):5-14. PubMed ID: 21955459
[TBL] [Abstract][Full Text] [Related]
7. Sodium glucose co-transporter 2 (SGLT2) inhibitors: novel antidiabetic agents.
Washburn WN
Expert Opin Ther Pat; 2012 May; 22(5):483-94. PubMed ID: 22583331
[TBL] [Abstract][Full Text] [Related]
8. Energy balance and metabolic changes with sodium-glucose co-transporter 2 inhibition.
Rajeev SP; Cuthbertson DJ; Wilding JP
Diabetes Obes Metab; 2016 Feb; 18(2):125-34. PubMed ID: 26403227
[TBL] [Abstract][Full Text] [Related]
9. Development of sotagliflozin, a dual sodium-dependent glucose transporter 1/2 inhibitor.
Lapuerta P; Zambrowicz B; Strumph P; Sands A
Diab Vasc Dis Res; 2015 Mar; 12(2):101-10. PubMed ID: 25690134
[TBL] [Abstract][Full Text] [Related]
10. Renal glucose reabsorption inhibitors to treat diabetes.
Bailey CJ
Trends Pharmacol Sci; 2011 Feb; 32(2):63-71. PubMed ID: 21211857
[TBL] [Abstract][Full Text] [Related]
11. Emerging sodium/glucose co-transporter 2 inhibitors for type 2 diabetes.
Boyle LD; Wilding JP
Expert Opin Emerg Drugs; 2013 Sep; 18(3):375-91. PubMed ID: 23968378
[TBL] [Abstract][Full Text] [Related]
12. The potential of sodium glucose cotransporter 2 (SGLT2) inhibitors to reduce cardiovascular risk in patients with type 2 diabetes (T2DM).
Basile JN
J Diabetes Complications; 2013; 27(3):280-6. PubMed ID: 23375850
[TBL] [Abstract][Full Text] [Related]
13. Renal sodium-glucose cotransporter inhibition in the management of type 2 diabetes mellitus.
Abdul-Ghani MA; Norton L; DeFronzo RA
Am J Physiol Renal Physiol; 2015 Dec; 309(11):F889-900. PubMed ID: 26354881
[TBL] [Abstract][Full Text] [Related]
14. The role of the kidneys in glucose homeostasis in type 2 diabetes: clinical implications and therapeutic significance through sodium glucose co-transporter 2 inhibitors.
Wilding JP
Metabolism; 2014 Oct; 63(10):1228-37. PubMed ID: 25104103
[TBL] [Abstract][Full Text] [Related]
15. Role of sodium-glucose cotransporter 2 (SGLT 2) inhibitors in the treatment of type 2 diabetes.
Abdul-Ghani MA; Norton L; Defronzo RA
Endocr Rev; 2011 Aug; 32(4):515-31. PubMed ID: 21606218
[TBL] [Abstract][Full Text] [Related]
16. Sodium-glucose co-transporter-2 inhibitors: an emerging new class of oral antidiabetic drug.
Idris I; Donnelly R
Diabetes Obes Metab; 2009 Feb; 11(2):79-88. PubMed ID: 19125776
[TBL] [Abstract][Full Text] [Related]
17. Familial renal glucosuria and SGLT2: from a mendelian trait to a therapeutic target.
Santer R; Calado J
Clin J Am Soc Nephrol; 2010 Jan; 5(1):133-41. PubMed ID: 19965550
[TBL] [Abstract][Full Text] [Related]
18. SGLT2 inhibitors: a new emerging therapeutic class in the treatment of type 2 diabetes mellitus.
Ghosh RK; Ghosh SM; Chawla S; Jasdanwala SA
J Clin Pharmacol; 2012 Apr; 52(4):457-63. PubMed ID: 21543663
[TBL] [Abstract][Full Text] [Related]
19. C-aryl glucosides substituted at the 4'-position as potent and selective renal sodium-dependent glucose co-transporter 2 (SGLT2) inhibitors for the treatment of type 2 diabetes.
Xu B; Feng Y; Cheng H; Song Y; Lv B; Wu Y; Wang C; Li S; Xu M; Du J; Peng K; Dong J; Zhang W; Zhang T; Zhu L; Ding H; Sheng Z; Welihinda A; Roberge JY; Seed B; Chen Y
Bioorg Med Chem Lett; 2011 Aug; 21(15):4465-70. PubMed ID: 21737266
[TBL] [Abstract][Full Text] [Related]
20. Beyond Glycosuria: Exploring the intrarenal effects of SGLT₋₂ inhibition in diabetes.
Thomas MC; Jandeleit-Dahm K; Bonnet F
Diabetes Metab; 2014 Dec; 40(6 Suppl 1):S17-22. PubMed ID: 25554067
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]